ACUTE EFFECTS OF MASSIVE TRANSFUSION OF A BOVINE HEMOGLOBIN BLOOD SUBSTITUTE IN A CANINE MODEL OF HEMORRHAGIC-SHOCK

被引：40

作者：

HARRINGER, W ^{[1
]}

HODAKOWSKI, GT ^{[1
]}

SVIZZERO, T ^{[1
]}

JACOBS, EE ^{[1
]}

VLAHAKES, GJ ^{[1
]}

TREASURE, T ^{[1
]}

机构：

[1] MASSACHUSETTS GEN HOSP, DEPT SURG, BOSTON, MA 02114 USA

来源：

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY | 1992年 / 6卷 / 12期

关键词：

BLOOD SUBSTITUTES; HEMORRHAGIC SHOCK; HEMODYNAMICS; OXYGEN METABOLISM; DOGS;

D O I：

10.1016/1010-7940(92)90189-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The capability of stroma-free hemoglobin solutions to act as a plasma expander with oxygen and carbon dioxide transport properties has encouraged the idea of their possible use in settings of massive blood loss. Using a canine hemorrhagic shock model (systolic arterial pressure less-than-or-equal-to 50 torr for 60 min), we evaluated the efficacy of an ultra-pure stroma-free bovine hemoglobin solution (PBHg) as a resuscitation fluid in hypovolemic and acidotic animals, using homologous blood (PRBC) and 10% human serum albumin (HSA) as control solutions. Following volume replacement, dogs were studied for 2 h under anesthesia and for 4 h subsequently while awake. Resuscitation with PBHg (30 +/- 3 ml/kg) was able to restore stable hemodynamics and correct acidosis to an extent comparable to that in animals treated with PRBC. Additionally, oxygen transport was maintained at a higher level than that in dogs treated with HSA. Administration of PBHg in this shock model revealed no significant cardiopulmonary toxicity or adverse effects. These short-term results suggest that PBHg may be useful for effective resuscitation after major blood loss.

引用

页码：649 / 654

页数：6

共 14 条

[1]

Breepoel P.M., Kreuzer F., Hazevoet M., Interaction of organic phosphates with bovine hemoglobin: I. Oxylabile and phosphate-labile proton binding, Pflügers Arch, 389, pp. 219-225, (1981)

[2]

Cochin A., DasGupta T.K., DeWoskin R., Moss G.S., Immunogenic properties of stroma vs stroma-free hemoglobin solution, Surg Forum, 23, pp. 19-21, (1972)

[3]

Cumming P.D., Wallace E.L., Schorr J.B., Dodd R.Y., Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative, N Engl J Med, 321, pp. 941-946, (1989)

[4]

Dayhoff M.O., Atlas of protein sequence and structure, pp. 191-219, (1976)

[5]

Lee R., Atsumi N., Jacobs E.E., Austen W.G., Vlahakes G.J., Ultrapure, stroma-free, polymerized bovine hemoglobin solution

[6]

evaluation of renal toxicity, J Surg Res, 47, pp. 407-411, (1989)

[7]

Moss G.S., DeWoskin R., Cochin A., Stroma-free hemoglobin. I. Preparation and observations on in vitro changes in coagulation, Surgery, 74, pp. 198-203, (1973)

[8]

Ovary Z., Antigenicity of hemoglobin and its constituents, Immunochem, 1, pp. 214-248, (1964)

[9]

Rabiner S.F., Hebert J.R., Lopas H., Friedman L.H., Evaluation of a stroma-free hemoglobin solution for use as a plasma expander, J Exp Med, 126, pp. 1127-1142, (1967)

[10]

Savitsky J.P., Doczi J., Black J., Arnold J.D., A clinical safety trial of stroma-free hemoglobin solution for use as a plasma expander, Clin Pharmacol Ther, 23, pp. 73-80, (1978)

← 1 2 →